Telix Pharmaceuticals Limited American Depositary Shares (TLX)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach a commercial-stage radiopharmaceutical company with caution, because the science can be wonderful but the investment case must still be grounded in numbers. Telix develops therapeutic and diagnostic radioactive medicines; it has three segments—Precision Medicine, Therapeutics, and Manufacturing Solutions—and its lead candidate TLX591 is in Phase 3 for advanced prostate cancer. At the 2026-10-13 close of $10.92, the market cap was $3.4B. FairStock’s calculations show a P/E of 109.20, P/B of 7.58, ROE of 7.36%, ROCE of 2.71%, and debt-to-equity of 1.19. Those are not the marks of a mature, high-return compounder. The Graham Number is only $1.80, implying a margin of safety of -506.67%; the price is far above what current earnings and book value would justify. The Piotroski F-Score of 2/9 and Altman Z-Score of 2.45 suggest fragile financial strength. The FairStock Score is 20/100, and the Lynch category is none because there are only 0 years of filed results, needing 3. Growth data for revenue and profit are not available, and there is no dividend. A beta of 0.60 is mild, and the 52-week range of $6.28 to $13.11 shows the market has swung widely. The key is whether TLX591 and the broader radiopharma pipeline can produce durable profits. Until I see filed evidence of rising revenue, positive earnings, and better returns on capital, I view this as a speculative pipeline story rather than a Graham-style bargain.

In plain English: Telix makes radioactive medicines to help diagnose and treat cancer. The business is still early in its profit story, with low earnings, some debt, and weak financial strength. At $10.92 on 2026-10-13, the shares look expensive compared with what the company currently earns and its accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer